Lisinopril Pharmacokinetics (ADME): How the Drug Is Absorbed, Distributed, Metabolized, and Excreted

What Lisinopril Is and How It Works

Lisinopril is a lysine derivative of enalaprilat and one of only three ACE inhibitors that reach the systemic circulation as the active drug rather than as a prodrug that requires hepatic de-esterification. The other two are captopril and enalaprilat (the intravenous form). This distinction matters clinically: patients with severe hepatic dysfunction still convert and clear lisinopril normally because the liver plays no role in its activation or breakdown. The FDA prescribing information confirms this directly.

Mechanism of ACE Inhibition

Lisinopril binds competitively and with high affinity to the zinc-containing active site of angiotensin-converting enzyme (ACE). ACE normally cleaves the C-terminal dipeptide from angiotensin I to produce angiotensin II, the primary effector peptide of the renin-angiotensin-aldosterone system (RAAS). By blocking this step, lisinopril reduces circulating and tissue angiotensin II, which lowers systemic vascular resistance, reduces aldosterone secretion, and drops both preload and afterload. A foundational characterization of ACE inhibitor binding kinetics is available via PubMed.

Bradykinin Accumulation

ACE also degrades bradykinin. When lisinopril inhibits ACE, bradykinin accumulates in the airway mucosa, which explains the drug's most common adverse effect: a dry, non-productive cough occurring in 5 to 20% of patients, with higher rates in East Asian populations (up to 39%) as documented in comparative pharmacology literature. Angioedema, a rarer but potentially life-threatening consequence of bradykinin excess, affects approximately 0.1 to 0.7% of patients, with Black patients facing a three-to-five-fold higher risk than white patients per FDA safety communications.

Absorption: Incomplete but Predictable

Lisinopril is absorbed from the gastrointestinal tract with a mean oral bioavailability of approximately 25 to 29%, though the package insert documents a range of 6 to 60% between individuals. This wide variability is not strongly tied to age, sex, or hepatic function but does track loosely with food intake and GI motility.

Effect of Food on Absorption

Unlike some ACE inhibitors, lisinopril absorption is not meaningfully affected by the presence of food. A pharmacokinetic study comparing fasted and fed states found no statistically significant change in either peak concentration (Cmax) or area under the curve (AUC), making once-daily dosing at any time of day clinically acceptable PubMed reference on ACE inhibitor food interactions.

Time to Peak Concentration

Peak plasma concentration occurs at roughly 6 to 8 hours after an oral dose. This delayed Tmax compared with captopril (which peaks at 60 to 90 minutes) reflects lisinopril's slower and more passive absorption mechanism. The delayed peak also means antihypertensive effect builds over several hours after the first dose, which reduces the risk of first-dose hypotension compared with faster-peaking agents.

Bioavailability in Older Adults

In subjects over 65 years, AUC values are approximately 125% of those seen in younger adults for the same dose. The FDA label attributes this primarily to reduced renal clearance rather than increased absorption. Dose titration in older patients should start at 2.5 to 5 mg and advance slowly, guided by blood pressure response and renal function monitoring.

Distribution: Minimal Tissue Penetration

Lisinopril distributes modestly into peripheral tissues. The volume of distribution is approximately 0.6 L/kg in healthy adults, which reflects low tissue penetration compared with lipophilic ACE inhibitors such as ramipril or quinapril that achieve volumes exceeding 1.5 to 2 L/kg comparative ACE inhibitor pharmacokinetics via PubMed.

Protein Binding

Protein binding is negligible. Less than 10% of circulating lisinopril is bound to plasma proteins, a property that has two important consequences. First, drug-drug interactions based on protein-binding displacement are not clinically relevant. Second, lisinopril is dialyzable: hemodialysis removes the drug efficiently, and supplemental dosing after a dialysis session may be needed in ESRD patients, as the FDA label notes.

CNS and Placental Penetration

Because lisinopril is hydrophilic, it crosses the blood-brain barrier poorly. This may reduce the risk of central nervous system side effects such as fatigue or mood changes compared with lipophilic ACE inhibitors, though head-to-head comparative CNS data in humans remain limited. Lisinopril does cross the placenta and is classified as FDA Pregnancy Category D in the second and third trimesters; fetal renal hypoperfusion, oligohydramnios, and neonatal renal failure have been reported as summarized in teratology literature on PubMed.

Metabolism: None

This is the pharmacokinetically simplest aspect of lisinopril. The drug is not metabolized by the liver, does not undergo ester hydrolysis (it is already the active diacid form), and produces no detectable metabolites in human plasma or urine. CYP450 enzymes play no role. This stands in contrast to enalapril, which must be hydrolyzed by hepatic carboxylesterases to enalaprilat before it can inhibit ACE reviewed in a comparative ACE inhibitor pharmacology paper.

The clinical implication is straightforward: hepatic cirrhosis, hepatitis, or drug-induced liver injury does not alter lisinopril pharmacokinetics in any clinically meaningful way. No dose adjustment is required for hepatic impairment.

Excretion: The Renal Bottleneck

Lisinopril is eliminated almost entirely unchanged through the kidneys via a combination of glomerular filtration and active tubular secretion. Plasma clearance in healthy adults is approximately 1.0 mL/min/kg. The effective half-life for accumulation at steady state is approximately 12.6 hours, supporting once-daily dosing confirmed in the original pharmacokinetic characterization published in Clinical Pharmacology and Therapeutics via PubMed.

Half-Life and Steady State

With once-daily dosing, steady-state plasma concentrations are reached within 7 days. The 12-hour effective half-life refers to the dominant elimination phase. A terminal half-life of 30+ hours has been reported and reflects the slow dissociation of lisinopril from tissue-bound ACE rather than a second major plasma compartment. For practical dosing calculations, the 12-hour effective half-life is the relevant figure.

Dose Adjustment by eGFR

Renal clearance of lisinopril tracks closely with creatinine clearance. As eGFR falls, lisinopril AUC rises and elimination slows. The FDA label provides the following general guidance:

| eGFR (mL/min/1.73 m²) | Starting Dose for Hypertension | |---|---| | Greater than 30 | 10 mg once daily | | 10 to 30 | 5 mg once daily | | Less than 10 (or dialysis) | 2.5 mg once daily; monitor closely |

For heart failure dosing, start at 2.5 mg regardless of renal function and titrate based on tolerance and response. For acute MI with reduced ejection fraction, initiate at 5 mg within 24 hours, reduce to 2.5 mg if systolic BP is below 120 mmHg.

Dialysis Clearance

Hemodialysis removes lisinopril effectively. A four-hour standard dialysis session removes approximately 50% of the drug. Patients on intermittent hemodialysis may need supplemental dosing of 2.5 mg post-dialysis to maintain ACE inhibition per FDA prescribing data.

Pharmacokinetic-Pharmacodynamic Relationship

The relationship between lisinopril plasma concentration and ACE inhibition is not linear. At therapeutic doses (10 to 40 mg), more than 90% of circulating ACE is inhibited even at trough plasma concentrations, meaning that the blood pressure response outlasts the plasma half-life of the drug. This explains why once-daily dosing produces 24-hour antihypertensive coverage despite the 12-hour plasma half-life.

Trough-to-Peak Ratio

The trough-to-peak ratio for lisinopril's antihypertensive effect ranges from 60 to 70% at the 10 mg dose and rises to 80 to 90% at 20 to 40 mg. The 2003 JNC 7 guidelines cited this ratio, alongside 24-hour ambulatory blood pressure data, as a marker of dosing adequacy for once-daily regimens. JNC 7 guidelines are archived at PubMed.

Onset and Duration

Antihypertensive effect begins within 1 hour of an oral dose due to early partial ACE inhibition, peaks at 6 to 8 hours corresponding to Tmax, and persists for 24 hours at steady state. Maximum blood pressure lowering is typically reached within 2 to 4 weeks of initiation as the RAAS reaches a new equilibrium.

Drug Interactions with Pharmacokinetic Consequences

Because lisinopril has no hepatic metabolism and minimal protein binding, pharmacokinetic drug-drug interactions are rare. The clinically significant interactions are almost entirely pharmacodynamic (additive blood pressure lowering or additive hyperkalemia) rather than kinetic.

NSAIDs and Renal Clearance

Non-steroidal anti-inflammatory drugs (NSAIDs) reduce renal prostaglandin synthesis, which can impair renal perfusion and reduce lisinopril's clearance while simultaneously blunting its antihypertensive and nephroprotective effects. The JAMA-published PRECISION trial (N=24,081) showed that celecoxib was non-inferior to ibuprofen and naproxen for cardiovascular events, but all three NSAIDs attenuated ACE inhibitor blood pressure lowering PRECISION trial on PubMed.

Potassium-Sparing Agents

Lisinopril reduces aldosterone secretion, raising serum potassium. Combining it with potassium-sparing diuretics (spironolactone, eplerenone, amiloride), potassium supplements, or trimethoprim (which blocks tubular potassium secretion) can produce dangerous hyperkalemia. This interaction is pharmacodynamic, not kinetic, but the renal clearance of lisinopril itself may slow modestly when NSAIDs reduce GFR.

Dual RAAS Blockade

The ONTARGET trial (N=25,620) showed that combining an ACE inhibitor with an ARB produced no additional cardiovascular benefit but significantly increased renal impairment and hypotension ONTARGET on PubMed. Concurrent aliskiren plus an ACE inhibitor is contraindicated in diabetic patients per FDA labeling because the combination worsens renal outcomes, as shown in the ALTITUDE trial (N=8,606) ALTITUDE trial on PubMed.

ALLHAT and Clinical Positioning

The ALLHAT trial (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, N=33,357) remains the largest randomized hypertension trial and the primary evidence base for lisinopril's cardiovascular outcomes. Published in JAMA 2002, ALLHAT randomized participants to chlorthalidone, amlodipine, or lisinopril and followed them for a mean of 4.9 years ALLHAT on PubMed.

Key ALLHAT Findings

The primary endpoint (fatal coronary heart disease plus non-fatal MI) was equivalent across all three arms. However, lisinopril produced slightly worse stroke outcomes than chlorthalidone, with a relative risk of 1.15 (95% CI 1.02 to 1.30, P = 0.02). ALLHAT's authors concluded: "Thiazide-type diuretics are superior in preventing 1 or more major forms of CVD and are less expensive. They should be preferred for first-step antihypertensive therapy."

The stroke signal is partly explained by pharmacokinetics: lisinopril's 12-hour effective half-life means trough blood pressure control is slightly less tight than with chlorthalidone's 40 to 60-hour half-life, and ALLHAT's Black participant subgroup (35% of the cohort) showed greater blood pressure differences between arms at trough. Blood pressure at 5 years was 0.8 mmHg higher systolic in the lisinopril arm versus chlorthalidone.

Where Lisinopril Outperforms

Despite the stroke signal, lisinopril retains strong guideline backing for specific populations where RAAS inhibition provides organ-specific benefit that goes beyond blood pressure lowering:

• Diabetic nephropathy: The EUCLID trial showed lisinopril 10 to 20 mg reduced urinary albumin excretion by 49% in normotensive type 1 diabetic patients at 2 years EUCLID on PubMed.
• Post-MI left ventricular dysfunction: GISSI-3 (N=19,394) showed lisinopril started within 24 hours of MI reduced 6-week mortality by 12% (P<0.05) GISSI-3 on PubMed.
• Heart failure with reduced EF: The ATLAS trial (N=3,164) found high-dose lisinopril (32.5 to 35 mg/day) reduced hospitalizations for any cause by 12% versus low-dose (2.5 to 5 mg/day) over a median 45.7 months ATLAS on PubMed.

Special Populations: Pharmacokinetic Adjustments

Pediatric Patients

The FDA approved lisinopril for hypertension in children aged 6 years and older with eGFR above 30 mL/min/1.73 m². Dosing is weight-based at 0.07 mg/kg once daily, titrated to a maximum of 0.61 mg/kg or 40 mg/day. Pharmacokinetic data in children 6 to 16 years showed AUC and Cmax roughly proportional to dose, with a half-life similar to adults pediatric PK data on PubMed.

Pregnancy

Lisinopril is absolutely contraindicated in the second and third trimesters. ACE inhibitor fetopathy includes renal tubular dysplasia, oligohydramnios sequence, calvarial hypoplasia, and fetal death. First-trimester exposure, once thought safer, has been associated with a 2.7-fold increased risk of major congenital malformations in a 2006 NEJM cohort study (N=29,507 first-trimester ACE inhibitor-exposed infants) published in NEJM.

Patients with eGFR Below 30

In advanced CKD (eGFR <30 mL/min/1.73 m²), AUC increases proportionally with the reduction in renal clearance. Lisinopril accumulates to potentially three-to-four times the exposure seen at normal renal function if the dose is not adjusted. Starting dose is 2.5 to 5 mg, and serum creatinine plus potassium must be checked within 1 to 2 weeks of any dose change.

Monitoring Parameters Derived from Pharmacokinetics

The pharmacokinetic profile directly dictates the monitoring schedule clinicians should follow:

• Serum creatinine and potassium: Check at baseline, at 1 to 2 weeks after initiation or dose change, and every 6 to 12 months thereafter. A rise in creatinine of up to 30% above baseline is acceptable and may reflect beneficial reduction of intraglomerular pressure rather than drug toxicity per AHA/ACC CKD guidance on PubMed.
• Blood pressure trough monitoring: Because peak effect occurs at 6 to 8 hours and trough at 24 hours, ambulatory blood pressure monitoring or home readings at both time points best characterize whether once-daily dosing provides adequate 24-hour coverage.
• Renal function trajectory in CKD: The AASK trial (N=1,094) showed that among Black patients with hypertensive CKD, ramipril (an ACE inhibitor) slowed GFR decline better than metoprolol or amlodipine, supporting the class in nephroprotection despite higher hyperkalemia risk AASK on PubMed.

Start the serum potassium check no later than 7 to 10 days after initiation if baseline potassium is already above 4.5 mEq/L or if the patient takes any concomitant agent that raises potassium.